Avalo Therapeutics’ $185 Million PIPE

Schulte Roth & Zabel represented Commodore Capital in the transaction.In connection with its acquisition of AlmataBio, Avalo Therapeutics, Inc. issued a PIPE consisting of preferred stock…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Laura Testa

Author: Laura Testa

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here